Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: GlobeNewswire
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecu
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]Seeking Alpha
- Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public OfferingGlobeNewswire
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
GLUE
Sec Filings
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- 1/9/26 - Form SCHEDULE
- GLUE's page on the SEC website